[Chemotherapy in advanced transitional cell carcinoma of the urinary tract. Phase II trial of a combination of doxorubicin and cisplatin].
Between January 1, 1983 and December 31, 1984, 18 patients with advanced transitional cell carcinoma of the urothelium were treated in a Phase II trial with doxorubicin 45 mg/sqm plus cisplatin 90/mg/sqm/day every four weeks. 17 patients were evaluable for response. There were: 4 partial responses (24% of response objective effects, 95% confidence limits are 15% and 33%) and 13 failures. The median survival was 18.5 months for responders and 10 months for non responders.
Ribrag
V
V
Département de Médecine, Institut Gustave Roussy, Villejuif.
Ghnassia
M
M
Théodore
C
C
Ghosn
M
M
Piot
G
G
Beurton
D
D
Cukier
J
J
Droz
J P
JP
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014571:Urologic Neoplasms / Q000188:drug therapy* / Q000401:mortality
D004317:Doxorubicin; D002945:Cisplatin
Chimiothérapie des stades avancés de carcinomes à cellules transitionnelles des voies urinaires. Essai phase II d'une association de doxorubicine et de cisplatine.